Exercise program for adults with severe asthma starting biologics

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial examines whether an individually tailored exercise program can improve exercise capacity and asthma control in adults with severe asthma who are beginning biologic treatment. Primary outcome is change in peak oxygen uptake during cardiopulmonary exercise testing. Secondary outcomes include asthma symptoms, exacerbation frequency, lung function, quality of life, and body composition, with the study conducted at Helsinki University Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age over 18 years
* Physician-diagnosed severe asthma defined with the GINA criteria and with a decision to initiate biological treatment (omalizumab, mepolizumab, benralizumab, dupilumab or tezepelumab) for severe asthma

Exclusion Criteria:

* Upcoming major surgery
* Acute musculoskeletal disease which unables regular exercise
* Inability to commit to the appointments and the exercise plan due to exhaustion or fatigue
* Pregnancy

Where it's running

• Helsinki University Hospital
  Helsinki, Finland Recruiting

Study contacts

• Study coordinator: Hanna Hisinger-Mölkänen, MD, PhD
• Email: hanna.hisinger-molkanen@hus.fi
• Phone: +358 40 6654484

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding the experiences of young adults with severe asthma

  This study is trying to understand the daily challenges and support needs of young adults aged 16-25 with severe asthma to help improve their care and outcomes.

  Recruiting Manchester University NHS Foundation Trust · Manchester, Greater · NCT06681545

• Predicting response to Benralizumab in severe asthma patients

  This study is testing if a specific blood test can help predict how well people with severe asthma will respond to the medication Benralizumab.

  Recruiting at 15 sites Phase 4 Nantes University Hospital · Aix-en-Provence and 19 other locations · NCT04565483

• Chronic Respiratory Disease Participant Engagement

  This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

  Recruiting Richmond Pharmacology Limited · London · NCT07924462

• HB0056 in adults with moderate to severe asthma

  This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.

  Recruiting at 2 sites Phase 1/2 Shanghai Huaota Biopharmaceutical Co., Ltd. · Beijing and 1 other locations · NCT07899996

• Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations

  This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.

  Recruiting at 4 sites Phase 3 Pfizer · River Forest, Illinois and 11 other locations · NCT07869043

• Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma

  This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.

  Recruiting Phase 1 Chiesi Farmaceutici S.p.A. · Leeds and 2 other locations · NCT07851623

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.